Nanovibronix Inc
NAOV4.020USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.06MMarket Cap
LossP/E TTM
More Details of Nanovibronix Inc Company
NanoVibronix, Inc. is a medical device company focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The Company's primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use.
Nanovibronix Inc Info
Ticker SymbolNAOV
Company nameNanovibronix Inc
IPO dateApr 24, 2015
CEOBesser (Doron)
Number of employees15
Security typeOrdinary Share
Fiscal year-endApr 24
Address969 Pruitt Piace
CityTYLER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75703
Phone19142333004
Websitehttps://nanovibronix.com/
Ticker SymbolNAOV
IPO dateApr 24, 2015
CEOBesser (Doron)
Company Executives of Nanovibronix Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
462.00K
93.52%
New Zealand
20.00K
4.05%
Europe
8.00K
1.62%
Other
4.00K
0.81%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 3
Updated: Wed, Dec 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.47%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
Other
98.25%
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.47%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
Other
98.25%
Shareholder Types
Shareholders
Proportion
Holding Company
0.76%
Investment Advisor/Hedge Fund
0.47%
Hedge Fund
0.42%
Investment Advisor
0.11%
Other
98.23%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
17
5.95K
0.68%
+2.34K
2025Q2
26
142.96K
5.53%
+80.02K
2025Q1
26
100.49K
7.64%
+70.73K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
2023Q2
41
49.26K
2.96%
-111.70K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alpha Capital Aktiengesellschaft
8.25K
0.95%
+4.93K
+148.55%
May 16, 2025
Geode Capital Management, L.L.C.
--
0%
-205.00
-100.00%
Mar 31, 2025
Armistice Capital LLC
3.99K
0.46%
+3.99K
--
Mar 31, 2025
Tower Research Capital LLC
226.00
0.03%
+124.00
+121.57%
Jun 30, 2025
The Vanguard Group, Inc.
--
0%
-274.00
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
1.37K
0.16%
+854.00
+165.50%
Jun 30, 2025
Fashek (Christopher M)
34.00
0%
--
--
May 16, 2025
SBI Securities Co., Ltd.
--
0%
--
--
Jun 30, 2025
BofA Global Research (US)
1.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Date
Type
Ratio
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Nanovibronix Inc?
The top five shareholders of Nanovibronix Inc are:
Alpha Capital Aktiengesellschaft holds 8.25K shares, accounting for 0.95% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Armistice Capital LLC holds 3.99K shares, accounting for 0.46% of the total shares.
Tower Research Capital LLC holds 226.00 shares, accounting for 0.03% of the total shares.
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Alpha Capital Aktiengesellschaft holds 8.25K shares, accounting for 0.95% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Armistice Capital LLC holds 3.99K shares, accounting for 0.46% of the total shares.
Tower Research Capital LLC holds 226.00 shares, accounting for 0.03% of the total shares.
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Nanovibronix Inc?
The top three shareholder types of Nanovibronix Inc are:
Alpha Capital Aktiengesellschaft
Geode Capital Management, L.L.C.
Armistice Capital LLC
Alpha Capital Aktiengesellschaft
Geode Capital Management, L.L.C.
Armistice Capital LLC
How many institutions hold shares of Nanovibronix Inc (NAOV)?
As of 2025Q3, 17 institutions hold shares of Nanovibronix Inc, with a combined market value of approximately 5.95K, accounting for 0.68% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.85%.
What is the biggest source of revenue for Nanovibronix Inc?
In FY2025Q2, the -- business generated the highest revenue for Nanovibronix Inc, amounting to -- and accounting for --% of total revenue.
